These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 35224665)
1. CD36: an emerging therapeutic target for cancer and its molecular mechanisms. Ruan C; Meng Y; Song H J Cancer Res Clin Oncol; 2022 Jul; 148(7):1551-1558. PubMed ID: 35224665 [TBL] [Abstract][Full Text] [Related]
2. CD36 tango in cancer: signaling pathways and functions. Wang J; Li Y Theranostics; 2019; 9(17):4893-4908. PubMed ID: 31410189 [TBL] [Abstract][Full Text] [Related]
3. CD36: The Bridge between Lipids and Tumors. Zhou X; Su M; Lu J; Li D; Niu X; Wang Y Molecules; 2024 Jan; 29(2):. PubMed ID: 38276607 [TBL] [Abstract][Full Text] [Related]
4. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Jiang M; Wu N; Xu B; Chu Y; Li X; Su S; Chen D; Li W; Shi Y; Gao X; Zhang H; Zhang Z; Du W; Nie Y; Liang J; Fan D Theranostics; 2019; 9(18):5359-5373. PubMed ID: 31410220 [TBL] [Abstract][Full Text] [Related]
5. Fatty-acid receptor CD36 functions as a hydrogen sulfide-targeted receptor with its Cys333-Cys272 disulfide bond serving as a specific molecular switch to accelerate gastric cancer metastasis. Wang R; Tao B; Fan Q; Wang S; Chen L; Zhang J; Hao Y; Dong S; Wang Z; Wang W; Cai Y; Li X; Bao T; Wang X; Qiu X; Wang K; Mo X; Kang Y; Wang Z EBioMedicine; 2019 Jul; 45():108-123. PubMed ID: 31262715 [TBL] [Abstract][Full Text] [Related]
6. CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease. Glatz JFC; Heather LC; Luiken JJFP Physiol Rev; 2024 Apr; 104(2):727-764. PubMed ID: 37882731 [TBL] [Abstract][Full Text] [Related]
7. Exogenous lipids promote the growth of breast cancer cells via CD36. Zhao J; Zhi Z; Wang C; Xing H; Song G; Yu X; Zhu Y; Wang X; Zhang X; Di Y Oncol Rep; 2017 Oct; 38(4):2105-2115. PubMed ID: 28765876 [TBL] [Abstract][Full Text] [Related]
8. CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis. Glatz JFC; Nabben M; Luiken JJFP Curr Opin Lipidol; 2022 Apr; 33(2):103-111. PubMed ID: 35125400 [TBL] [Abstract][Full Text] [Related]
9. Lipid partitioning, incomplete fatty acid oxidation, and insulin signal transduction in primary human muscle cells: effects of severe obesity, fatty acid incubation, and fatty acid translocase/CD36 overexpression. Bell JA; Reed MA; Consitt LA; Martin OJ; Haynie KR; Hulver MW; Muoio DM; Dohm GL J Clin Endocrinol Metab; 2010 Jul; 95(7):3400-10. PubMed ID: 20427507 [TBL] [Abstract][Full Text] [Related]
10. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. Glatz JFC; Luiken JJFP J Lipid Res; 2018 Jul; 59(7):1084-1093. PubMed ID: 29627764 [TBL] [Abstract][Full Text] [Related]
11. Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance. Luiken JJFP; Nabben M; Neumann D; Glatz JFC Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165775. PubMed ID: 32209364 [TBL] [Abstract][Full Text] [Related]
12. Regulation of the subcellular trafficking of CD36, a major determinant of cardiac fatty acid utilization. Glatz JF; Nabben M; Heather LC; Bonen A; Luiken JJ Biochim Biophys Acta; 2016 Oct; 1861(10):1461-71. PubMed ID: 27090938 [TBL] [Abstract][Full Text] [Related]
13. Greater transport efficiencies of the membrane fatty acid transporters FAT/CD36 and FATP4 compared with FABPpm and FATP1 and differential effects on fatty acid esterification and oxidation in rat skeletal muscle. Nickerson JG; Alkhateeb H; Benton CR; Lally J; Nickerson J; Han XX; Wilson MH; Jain SS; Snook LA; Glatz JFC; Chabowski A; Luiken JJFP; Bonen A J Biol Chem; 2009 Jun; 284(24):16522-16530. PubMed ID: 19380575 [TBL] [Abstract][Full Text] [Related]
15. The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target. Feng WW; Zuppe HT; Kurokawa M Cells; 2023 Jun; 12(12):. PubMed ID: 37371076 [TBL] [Abstract][Full Text] [Related]
16. CD36 as a target for metabolic modulation therapy in cardiac disease. Glatz JFC; Wang F; Nabben M; Luiken JJFP Expert Opin Ther Targets; 2021 May; 25(5):393-400. PubMed ID: 34128755 [No Abstract] [Full Text] [Related]
17. CD36 Signal Transduction in Metabolic Diseases: Novel Insights and Therapeutic Targeting. Karunakaran U; Elumalai S; Moon JS; Won KC Cells; 2021 Jul; 10(7):. PubMed ID: 34360006 [TBL] [Abstract][Full Text] [Related]
18. Metabolic challenges reveal impaired fatty acid metabolism and translocation of FAT/CD36 but not FABPpm in obese Zucker rat muscle. Han XX; Chabowski A; Tandon NN; Calles-Escandon J; Glatz JF; Luiken JJ; Bonen A Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E566-75. PubMed ID: 17519284 [TBL] [Abstract][Full Text] [Related]
19. Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. Bharadwaj KG; Hiyama Y; Hu Y; Huggins LA; Ramakrishnan R; Abumrad NA; Shulman GI; Blaner WS; Goldberg IJ J Biol Chem; 2010 Dec; 285(49):37976-86. PubMed ID: 20852327 [TBL] [Abstract][Full Text] [Related]
20. CD36 favours fat sensing and transport to govern lipid metabolism. Li Y; Huang X; Yang G; Xu K; Yin Y; Brecchia G; Yin J Prog Lipid Res; 2022 Nov; 88():101193. PubMed ID: 36055468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]